Coronary flow reserve and asymmetric dimethylarginine levels: New measurements for identifying subclinical atherosclerosis in patients with psoriatic arthritis

Journal of Rheumatology

Volumn 38, Issue 8, 2011, Pages 1661-1664

  Atzeni, Fabiola ^a,b   Sarzi Puttini, Piercarlo ^b   Sitia, Simona ^c   Tomasoni, Livio ^c   Gianturco, Luigi ^c   Battellino, Michele ^b   Boccassini, Laura ^b   Colonna, Vito De Gennaro ^c   Marchesoni, Antonio ^d   Turiel, Maurizio ^c  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UOC Day Hospital of Rheumatology   (Italy)

Author keywords

Asymmetric dimethylarginine; Cardiovascular involvement; Coronary flow reserve; Psoriatic arthritis

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N(G),N(G) DIMETHYLARGININE; NONSTEROID ANTIINFLAMMATORY AGENT; TRIACYLGLYCEROL;

ADULT; ANALYTICAL PARAMETERS; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BLOOD CELL COUNT; CARDIOVASCULAR PARAMETERS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY FLOW RESERVE; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; ECHOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; FEMALE; HUMAN; MALE; MORNING STIFFNESS; PAIN; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIATIC ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; TRIACYLGLYCEROL BLOOD LEVEL; VISUAL ANALOG SCALE;

ADULT; AGED; ARGININE; ARTHRITIS, PSORIATIC; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CAROTID ARTERY, COMMON; CORONARY CIRCULATION; DIPYRIDAMOLE; ECHOCARDIOGRAPHY, STRESS; ENZYME INHIBITORS; FEMALE; HUMANS; MIDDLE AGED; TUNICA INTIMA; TUNICA MEDIA;

EID: 79961103560     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.100893     Document Type: Article

References (16)

1. Wong K, Gladman DD, Husted J, Long JA, Farewell VT. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 1997;40:1868-72. (Pubitemid 27452539)
2. Gladman DD, Farewell VT, Wong K, Husted J. Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 1998;41:1103-10. (Pubitemid 28265412)
3. Mallbris L, Akre O, Branath F, Yin L, Lindelof B, Ekbom A, et al. Increased risk for cardiovascular mortality in psoriatic inpatients but not outpatients. Eur J Epidemiol 2004;19:225-30. (Pubitemid 38461682)
4. Tam LS, Tomlinson B, Chu TT, Li M, Leung YY, Kwok LW, et al. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls - the role of inflammation. Rheumatology 2008;47:718-23. (Pubitemid 351619219)
5. Kimhi O, Caspi D, Bornstein NM, Maharshak N, Gur A, Arbel Y, et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 2007;36:203-9. (Pubitemid 46188476)
6. Gonzalez-Juanatey C, Llorca J, Miranda-Filloy JA, Amigo-Diaz E, Testa A, Garcia-Porrua C, et al. Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007;57:287-93. (Pubitemid 47164092)
7. Gonzalez-Juanatey C, Llorca J, Amigo-Diaz E, Dierssen T, Martin J, Gonzalez-Gay MA. High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007;57:1074-80. (Pubitemid 47237336)
8. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999;99:1141-6. (Pubitemid 29120084)
9. Vallance P. Importance of asymmetrical dimethylarginine in cardiovascular risk. Lancet 2001;358:2096-7. (Pubitemid 34094893)
10. Turiel M, Atzeni F, Tomasoni L, de Portu S, Delfino L, Bodini BD, et al. Non-invasive assessment of coronary flow reserve and ADMA levels: a case-control study of early rheumatoid arthritis patients. Rheumatology 2009;48:834-9.
11. Atzeni F, Sarzi-Puttini P, De Blasio G, Delfino L, Tomasoni L, Turiel M. Preclinical impairment of coronary flow reserve in patients with rheumatoid arthritis. Ann NY Acad Sci 2007;1108:392-7. (Pubitemid 47528751)
12. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H; CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73. (Pubitemid 44205029)
13. Anthony S, Leiper J, Vallance P. Endogenous production of nitric oxide synthase inhibitors. Vasc Med 2005;10:S3-9. (Pubitemid 43137262)
14. Tam LS, Shang Q, Li EK, Tomlinson B, Chu TT, Li M, et al. Subclinical carotid atherosclerosis in patients with psoriatic arthritis. Arthritis Rheum 2008;59:1322-31.
15. Eder L, Zisman D, Barzilai M, Laor A, Rahat M, Rozenbaum M, et al. Subclinical atherosclerosis in psoriatic arthritis: a case-control study. J Rheumatol 2008;35:877-82. (Pubitemid 351747131)
16. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173-7. (Pubitemid 34304256)